7 HA'ESHEL ST., POB 3163, CAESAREA, L3
Highlights Clinical Data and Strong Physician Engagement for ProSense® Breast Cancer Cryoablation at EUSOBI 2026
Proxy Statement: Annual and Special General Meeting of Shareholders to Be Held on November 2, 2026
Seeks Permanent CPT Category I Code for Cryoablation Treatment
This Proxy Is Solicited On Behalf Of The Board Of Directors
Receives Regulatory Approval to Market ProSense® in China
Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
Announces Resignation of Mr. Vincent Chun Hung Chan from the Board of Directors
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(5)
No filings found
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Post-Effective Amendment to Registration Statement
Correspondence
Free Writing Prospectus